Background: A nontoxic chemopreventive intervention efficacious against different subtypes of breast cancer is still a clinically unmet need. The present study was undertaken to determine the efficacy of an Ayurvedic medicine phytochemical (Withaferin A, [WA]) for chemoprevention of breast cancer and to elucidate its mode of action. Methods: Chemopreventive efficacy of WA (4 and 8 mg/kg body weight) was determined using a rat model of breast cancer induced by N-methyl-N-nitrosourea (MNU; n ¼ 14 for control group, n ¼ 15 for 4 mg/kg group, and n ¼ 18 for 8 mg/kg group). The mechanisms underlying breast cancer chemoprevention by WA were elucidated by immunoblotting, biochemical assays, immunohistochemistry, and cytokine profiling using plasma and tumors from the MNU-rat (n ¼ 8-12 for control group, n ¼ 7-11 for 4 mg/kg group, and n ¼ 8-12 for 8 mg/kg group) and/or mouse mammary tumor virus-neu (MMTV-neu) models (n ¼ 4-11 for control group and n ¼ 4-21 for 4 mg/kg group). Inhibitory effect of WA on exit from mitosis and leptin-induced oncogenic signaling was determined using MCF-7 and/or MDA-MB-231 cells. All statistical tests were two-sided. Results: Incidence, multiplicity, and burden of breast cancer in rats were decreased by WA administration. For example, the tumor weight in the 8 mg/kg group was lower by about 68% compared with controls (8 mg/kg vs control, mean ¼ 2.76 vs 8.59, difference ¼ -5.83, 95% confidence interval of difference ¼ À9.89 to -1.76, P ¼ .004). Mitotic arrest and apoptosis induction were some common determinants of breast cancer chemoprevention by WA in the MNU-rat and MMTV-neu models. Cytokine profiling showed suppression of plasma leptin levels by WA in rats. WA inhibited leptin-induced oncogenic signaling in cultured breast cancer cells. Conclusion: WA is a promising chemopreventative phytochemical with the ability to inhibit at least two different subtypes of breast cancer.
Even though the clinical evidence for efficacy of these interventions for reduction of ER þ luminal-type breast cancer incidence is persuasive, they also have some side effects (5) (6) (7) (8) . A nontoxic chemopreventive intervention efficacious against different subtypes of breast cancer is still lacking. Naturally occurring small molecules isolated from edible and medicinal plants remain attractive for cancer chemoprevention (9) (10) (11) (12) . Withaferin A (WA) is one such promising phytochemical, present in the root and leaf of an Ayurvedic medicine plant (Withania somnifera), whose inhibitory effect on cancer cells was first realized in the late sixties (13) . Among different naturally occurring withanolides, WA is a much more potent inhibitor of breast cancer cell growth in vitro (14) . We were the first to provide evidence for in vitro and in vivo activity of WA against breast cancer, including prevention of ER -breast cancer in a mouse mammary tumor virus-neu (MMTV-neu) transgenic mouse model (15) (16) (17) . Building upon our previous in vitro observations of ER suppression, cell growth inhibition, and apoptosis induction by WA treatment in luminal-type human breast cancer cell lines (16, (18) (19) (20) , the primary objective of this study was to determine the in vivo efficacy of WA for chemoprevention of ER þ breast cancer using a rat model of chemically induced cancer with histological and genetic similarities with the human luminaltype disease (21, 22) . A secondary goal of the study was to identify common mechanistic biomarkers predictive of WA's efficacy in ER þ breast cancer in rats and ER -breast cancer in the MMTV-neu mouse model (17) .
Methods

Reagents and Cell Lines
Sources of the reagents and cell lines are provided in the Supplementary Methods (available online).
Power Calculation and Random Assignment
Use and care of rats for the chemoprevention study described herein was approved by the Institutional Animal Care and Use Committee of the University of Pittsburgh. Power calculation was based on tumor incidence (primary outcome) data from the published literature (23) . A power of 88% was estimated for detection of a group difference of 40% in cancer incidence at a P value of .05 with 20 rats per group. A total of 60 20-day-old female Sprague-Dawley rats were purchased from the Charles River Laboratories (Wilmington, MA) in three batches of 20 each and assigned to one of the three groups: control, 4 mg/kg body weight, and 8 mg/kg body weight. At 21 days of age, rats were injected intraperitoneally with 50 mg N-methyl-N-nitrosourea (MNU)/kg body weight in 0.9% normal saline. One week post-MNU injection, the rats either received vehicle (control group) or vehicle containing 4 mg/kg or 8 mg/kg WA by intraperitoneal injection five times per week for 10 weeks. The number of evaluable rats at the conclusion of the study was 14 for the control group, 15 for the 4 mg/kg group, and 18 for the 8 mg/kg group. Other details are provided in the Supplementary Methods (available online).
Determination of WA Levels
WA content in the rat plasma (n ¼ 6 for each group) and rat tumor tissues (n ¼ 6 for control and 4 mg/kg groups, and n ¼ 5 for 8 mg/kg group) was determined by mass spectrometry as detailed in the Supplementary Methods (available online).
Determination of Mitotic Index in Tumor Sections
Mitotic cells in hematoxylin and eosin (H&E)-stained mammary tumor sections from the MNU-rat (n ¼ 12 for control group, n ¼ 11 for 4 mg/kg group, and n ¼ 12 for 8 mg/kg group) and MMTV-neu models (n ¼ 11 for control group and n ¼ 21 for 4 mg/kg group) were counted as described in the Supplementary Methods (available online).
Cell Cycle Distribution in MCF-7 Cells In Vitro
Kinetics of the exit from mitosis in vitro was determined by flow cytometry using MCF-7 cells synchronized in the G 2 /M phase by treatment with nocodazole and then released either in drug-free medium or medium supplemented with 2 mM WA. The cells were collected at different time points (one, two, four, eight, and 24 hours) after release, and the percentage of G 2 /M and G 1 populations was determined by flow cytometry as described in the Supplementary Methods (available online).
Immunoblotting
Fresh-frozen tumors from rats (n ¼ 8 for control group, n ¼ 7 for 4 mg/kg group, and n ¼ 8 for 8 mg/kg group) and MMTV-neu mice (n ¼ 4 for both groups) were used for immunoblotting.
Preparations of tumor and cell lysates and the immunoblotting details are included in the Supplementary Methods (available online).
Determination of Metabolic Intermediates
Commercially available kits were used for measurement of plasma (n ¼ 12 for control group and n ¼ 9-10 for 8 mg/kg group) and tumor (n ¼ 11 for control group and n ¼ 8-11 for 8 mg/kg group) levels of lactate, malate, and acetyl-CoA as described in the Supplementary Methods (available online).
Measurement of Complex III Activity
Mitochondrial respiratory chain complex III (ubiquinol cytochrome c oxidoreductase) activity using rat tumors (n ¼ 9 for control group, n ¼ 8 for 4 mg/kg group, and n ¼ 9 for 8 mg/kg group) was measured as described by us previously with minor modifications (17) . Experimental details, including modifications, are included in the Supplementary Methods (available online).
Immunohistochemistry
Immunohistochemistry (IHC) was performed as described by us previously (17, 24, 25) . Details of IHC are described in the Supplementary Methods (available online). Stained rat tumor sections (n ¼ 12 for control group, n ¼ 11 for 4 mg/kg group, and n ¼ 12 for 8 mg/kg group) were analyzed using Aperio ImageScope software (Leica Biosystems Inc., Buffalo Grove, IL) (17).
Terminal Deoxynucleotidyl Transferase-Mediated dUTP Nick End Labeling Assay
The effect of WA treatment on tumor apoptosis in vivo was determined by terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay (n ¼ 12 for control group, n ¼ 11 for 4 mg/kg group, and n ¼ 12 for 8 mg/kg group) using a commercially available kit and by following the supplier's instructions that are detailed in the Supplementary Methods (available online).
Determination of Aldehyde Dehydrogenase 1 (ALDH1) Activity
Fresh frozen tumor specimens from the control (n ¼ 10) and 8 mg/kg WA treatment groups (n ¼ 10) were used to measure aldehyde dehydrogenase 1 (ALDH1) activity by flow cytometry using a commercially available kit essentially as described by us previously (26) and detailed in the Supplementary Methods (available online).
Cytokine Profiling
A commercially available kit was used to profile cytokines in the rat plasma (n ¼ 12 for control group, n ¼ 11 for 4 mg/kg group, and n ¼ 11 for 8 mg/kg group) and tumor lysates (n ¼ 12 for control group, n ¼ 10 for 4 mg/kg group, and n ¼ 11 for 8 mg/kg group) of control and WA treatment groups. Analytical details are described in more detail in the Supplementary Methods (available online).
Colony Formation and Cell Migration Assays
Details of colony formation and cell migration assays are included in the Supplementary Methods (available online).
Boyden chamber-based cell migration assay was done as previously described (27, 28) .
Statistical Analyses
Results are expressed as mean with corresponding 95% confidence interval (CI). The generalized linear mixed models were performed to evaluate treatment effects. The Poisson regression model was used to evaluate difference in tumor multiplicity (number of tumors per rat). Analysis of variance (ANOVA) was used to examine the treatment effects on cumulative tumor weight. Two sample comparisons were analyzed by unpaired Student's t test. Dunnett's method was used for multiple comparisons to a control alone. The P values for multiple group comparisons were adjusted using Bonferroni's method. All statistical tests were two-sided, and a statistical significance level was set at .05. Statistical analyses were performed using SAS v. 9.4 (SAS Institute, Cary, NC) or GraphPad Prism 6.07 (La Jolla, CA).
Results
Effect of WA on MNU-Induced Breast Cancer in Rats
The MNU rat model is an excellent choice for preclinical chemoprevention trials because 1) a single MNU injection produces highly reproducible ER þ breast tumors in rats with histological and genetic similarities to human luminal-type breast cancer (21, 22, 29) and 2) this model has been used to demonstrate chemopreventive efficacy of agents targeting hormonal axis, including tamoxifen and aromatase inhibitors (30, 31) . Except for a modest weight loss in the 4 mg/kg and 8 mg/kg groups on days 78 and 50, respectively, the body weights of the WA-treated rats did not differ from controls ( Figure 1A ). Figure 1B) . Chemoprevention of breast cancer after WA treatment was also reflected by a decrease in average number of tumors per rat ( Figure 1C ) and tumor weight ( Figure 1D Figure 1E ) and tumors ( Figure 1F ) of WA treatment groups. These results showed bioavailability of WA in the tumor and its inhibitory effects on incidence and burden of mammary tumors in rats.
Effect of WA Administration on Mitotic Index
Previous in vitro studies from our laboratory have revealed accumulation of mitotic cells in association with downregulation of b-Tubulin and its covalent modification at cysteine-303 by WA treatment in human breast cancer cells ( Figure 2A ) (14) . Representative H&E-stained sections from tumors of two different rats of the control and the 8 mg/kg WA treatment groups are shown in Figure 2B (mitotic cells are identified by arrows). Figure 2C ). Figure 2D shows immunoblots for p(S10)-Histone H3 using tumor lysates from different rats of each group. Figure 2E) . A trend for a decrease in the tumor levels of b-Tubulin in the WA treatment groups was discernible, but the difference was not significant from controls (Supplementary Figure 1 , available online). An increase in the number of mitotic cells in the tumors of the 8 mg/kg WA group compared with control ( Figure 2C ) could be due to increased mitosis and/or inhibition of exit from mitosis. To experimentally probe these possibilities, in vitro experiments were carried out using MCF-7 cells. The MCF-7 cells synchronized in the G 2 /M phase (4N) by treatment with nocodazole ( Figure 2F ) quickly resumed cell cycle progression when released in drug-free medium, as evidenced by a timedependent decrease in the G 2 /M population with a concomitant increase in G 1 phase cells ( Figure 2G ). A relatively higher proportion of the cells remained in the G 2 /M phase when the synchronized cells were released in WA-containing medium, indicating inhibition of exit from mitosis ( Figure 2G ).
We used archived H&E-stained tumor sections from controland WA-treated MMTV-neu mice (17) to test whether accumulation of mitotic cells was a disease subtype-independent effect of this agent. The number of mitotic cells per mm 2 Plasma specimens from different rats of each group were used for determination of WA levels. F) WA concentration in the tumor of control-and WA-treated rats. The lines in the scatter dot plot indicate mean WA levels and their 95% confidence intervals (error bars, n ¼ 6 for control and 4 mg/kg; n ¼ 5 for 8 mg/kg). Tumor tissues from different rats of each group were used for determination of WA levels. All P values were two-sided. shown are mean levels of metabolites and their 95% confidence intervals (error bars, n ¼ 12 for control ; n ¼ 9-10 for 8 mg/kg). Plasma samples from different rats of each group were used for determination of metabolite levels. Statistical significance of difference was analyzed by unpaired Student's t test. F) Tumor levels of lactate, malate, and acetyl-CoA in rats of control and WA treatment groups. Results shown are mean levels of metabolites and their 95% confidence intervals (error bars, n ¼ 11 for control; n ¼ 8-11 for 8 mg/kg). Tumor tissues from different rats of each group were used for determination of the levels of the specified metabolites. Statistical significance of difference was analyzed by unpaired Student's t test. All P values were two-sided. 
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glycolysis and tricarboxylic acid cycle (17) . The levels of key intermediates of glycolysis (lactate) and tricarboxylic acid cycle (malate), as well as acetyl-CoA, were lower in the plasma ( Figure 3E ) and/or tumors ( Figure 3F ) of the 8 mg/kg group rats compared with controls. These results indicate that inhibition of glycolysis and tricarboxylic acid cycle are common mechanisms of WA-mediated chemoprevention in ER þ (present study) and ER -breast cancers (17) .
Apoptotic Cell Death Biomarkers in Rat Tumors
Figure 4A summarizes a mechanistic model for WA-induced apoptosis in breast cancer from our own in vitro and in vivo findings (16, 17 Figure 4B ). Immunohistochemical staining for 8-OHdG, a biochemical marker of reactive oxygen species, in a representative tumor of the control group and the 8 mg/kg group is shown in Figure 4C . The H-score for 8-OHdG level was higher by 1.85-to 2.35-fold in the tumors of WA-treated rats compared with controls, but the difference was not significant ( Figure 4D ). We have shown previously that WA-induced apoptosis in cultured breast cancer cell lines is attenuated by knockdown of multidomain proapoptotic proteins Bax and Bak (16). Generally, the protein level of Bak, but not Bax, was higher in the tumors of WA-treated rats compared with controls ( Figure 4, E and F) . Cleavage of poly-(ADP-ribose) polymerase (cleaved PARP), another well-accepted marker of apoptosis, was higher in the tumors of WA-treated rats compared with controls ( Supplementary Figure 2, available online) . The number of TUNEL-positive cells per high-power field (green fluorescence in Figure 4G ) was significantly higher in rat tumors of the 8 mg/kg group compared with controls (8 mg/kg vs control, mean ¼ 28.79 Figure 4H ). Collectively, these results provided in vivo evidence for WA-induced apoptosis in rat mammary tumors.
Cell Proliferation and Neoangiogenesis in Rat Tumors
Even though WA is highly effective in suppressing in vitro proliferation of ER þ and ER -human breast cancer cells (16) , the H-score for proliferation marker Ki-67 ( Figure 5A ) was not different between the tumors of control and WA treatment groups ( Figure 5B ), consistent with data in MMTV-neu tumors (17) . The number of CD31-positive blood vessels per high-power field ( Figure 5C ) was lower in the tumors of WA-treated rats compared with controls, but the difference was not significant ( Figure 5D ).
Breast Cancer Stem Cell Biomarkers in Rat Tumors
With the growing evidence for a role of breast cancer stem cells (bCSC) in tumorigenesis and therapy resistance (32) , it is equally important to assess the efficacy of promising chemopreventive agents on this population. WA is a potent inhibitor of the bCSC population in vitro and in MMTV-neu tumors in vivo (26) . Forkhead box Q1 (FoxQ1) is one of the proteins implicated in bCSC maintenance (33, 34) . For example, we have shown recently that overexpression of FoxQ1 in MCF-7 and SUM159 cells increases ALDH1 activity and mammosphere number (34) . FoxQ1 protein level was visually lower in the tumors of WA treatment groups compared with controls ( Figure 5 , E and F). Figure 5G shows flow histograms for ALDH1 activity in dissociated cells from representative tumors of two different rats of the control and the 8 mg/kg groups. ALDH1 activity was lower in dissociated cells from the tumors of the 8 mg/kg group compared with controls with P ¼ .06 by two-sided Student's t test ( Figure 5H ).
Cytokine Profiling in Rat Plasma and Tumors
The circulating leptin level was lower in the rat plasma of the WA treatment groups compared with controls ( Table 1) . Levels of tumor cytokines were not different between the control and the WA treatment groups (Table 2 ).
In Vitro Effects of WA on Leptin-Induced Signaling 
Discussion
We have shown previously that the burden, but not the overall incidence, of ER -breast cancer in MMTV-neu mice is inhibited significantly by three times per week treatment with 0.1 mg WA per mouse (equates to $4 mg/kg body weight) for 28 weeks (17) . We reasoned that a higher dose and/or more frequent administration of WA might be necessary to achieve inhibition of breast cancer incidence. Generally, the rat equivalent of a mouse dose is approximately 50% lower because of metabolic differences (40) . Indeed, the WA regimen intensification with five times per week treatment in the present study (4 mg/kg and 8 mg/kg rat doses correspond to $8 and 16 mg/kg body weight for mice, respectively) resulted in inhibition of cancer incidence. Similar to the MMTV-neu study, the WA regimen was well tolerated by the rats. Because breast cancer is a heterogeneous disease, it is clinically attractive to identify chemopreventive interventions that are efficacious against different subtypes of the disease. Identification of a mechanistic biomarker is especially important for clinical development of a chemopreventive intervention. The present study identifies several disease subtype-independent biomarkers of WA potentially useful in future clinical investigations, including increased mitotic index in the tumor, decreased plasma and/or tumor levels of lactate, malate, and acetyl-CoA (noninvasive biomarkers in plasma), inhibition of tumor complex III activity, inhibition of bCSC fraction (tumor ALDH1 activity), Bak induction, and increased tumor cell apoptosis. Most of these biomarkers were similarly modulated by WA treatment in preclinical models of ER þ (present study) and ER -(MMTV-neu model; 17) breast cancers.
The present study shows that the protein level of FoxQ1 is significantly decreased in vivo in the mammary tumors of WAtreated rats. Thus, FoxQ1 appears to be a critical mechanistic target of bCSC inhibition by WA. Overexpression of FoxQ1 has been reported in high-grade basal-like breast cancers and associated with poor clinical outcome (33) . FoxQ1 is also implicated in promotion of epithelial-mesenchymal transition and cancer metastasis (33, 41, 42) . In this context, we have shown previously inhibition of epithelial-mesenchymal transition by WA in breast cancer cells (43) .
It is equally exciting to note that WA administration not only decreases circulating levels of leptin in vivo in the rat but also inhibits oncogenic signaling (STAT3 activation) induced by this adipokine in cultured human breast cancer cells. A role for leptin in breast carcinogenesis is substantiated by the epidemiological data, as well as by experimental studies (35, 36, 44, 45) . Leptin level is positively correlated with obesity (46) . Blood leptin levels were found to be greater than twofold higher in obese women than those with normal weight and body mass index (47) . In addition, both serum leptin levels and leptin and body mass index ratio were significantly greater in patients with breast cancer (36) . The mechanism underlying mammary tumor growth promotion by leptin is complex and involves activation/induction of multiple oncogenic signaling pathways, including STAT3 (38, 46) . The present study reveals in vitro inhibition of leptin-induced STAT3 activation, cell proliferation, and cell migration following WA exposure.
The intraperitoneal route of WA administration is a potential limitation of this study because only the oral administration is practical for chemopreventive intervention for chronic administration in high-risk subjects. Based on the results of a study published since submission of this article (48) , it is reasonable to postulate that chemoprevention of breast cancer may be plausible with oral WA administration. Specifically, oral administration of WA (3-5 mg/kg body weight) resulted in chemoprevention in a rather aggressive transgenic mouse model of prostate cancer (48) . A human equivalent of the oral 5 mg/kg body weight mouse dose is about 0.42 mg/kg (about 25 mg WA for a 60 kg body weight subject) based on guidance from the United States Food and Drug Administration Center for Drug Evaluation and Research. While the maximally tolerated dose for WA in humans is yet to be established, three times daily administration of 400 mg Withania somnifera extract (WSE; the plant from which WA is derived) for one month (equates to about 18 mg WA in each 400 mg WSE capsule) was not only well tolerated but also resulted in a statistically significant decrease in levels of serum triglycerides and fasting blood glucose (49) . Moreover, the no observed adverse effect level (NOAEL) of the same WSE preparation was 2000 mg/kg in a toxicity study in Wistar rats after daily oral administration for 28 days (50) . The LD 50 of oral WSE in Wistar rats was greater than 2000 mg/kg body weight (50) . We are encouraged by these findings, which would be helpful in the design of future clinical trials.
